receptors (CD23) on normal human lymphocytes. J.Exp. Med. 165:1459- 
1467, 1987. 
16. Sanders, V.M. , Fernandez- Bo tran, R. , Uhr, J.W., and Vitetta, E.S.: 
Interleukin-4 enhances the ability of antigen- specif ic B cells to 
form conjugates with T cells. J. Immunol. 139:2349-2354, 1987. 
17. Hart, P.H. , Vitti, G.F. , Burgess, D.R. , Whitty, G.A. , Piccoli, D.S., 
and Hamilton, J.A.: Potential anti-inflammatory effects of interleukin- 
4: Suppression of human monocyte tumor necrosis factor alpha, 
interleukin 1, and prostaglandin E 2 . Proc. Natl. Acad. Sci. USA 86: 
3803-3807, 1989. 
18. Tepper, R.I., Pattengale, P.K. , and Leder, P.: Murine interleukin- 4 
displays potent anti- tumor activity in vivo . Cell 57:503-512, 1989. 
19. Rosenberg, S.A., Spiess, P. ,. Lafreniere, R. : A new approach to the 
adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. 
Science 233:1318-1321, 1986. 
20. Barth, R.J., Bock, S.N., Mule, J.J. and Rosenberg, S.A.: Unique 
murine tumor- associated antigens identified by tumor infiltrating 
l 3 miphocytes . J. Immunol. 144:1531-1537, 1990. 
21. Topalian, S.L., Solomon, D. and Rosenberg, S.A.: Tumor- specific cytolysis 
by lymphocytes infiltrating human melanomas. J. Immunol. 
142:3714-3725, 1989. 
22. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D. , Topalian, 
S.L., Toy, S.T., Simon, P. , Lotze, M.T. , Yang, J.C., Seipp, C.A. , 
Cimpson, C. , Carter, C. , Bock, S., Schwartzentruber , D. , Wei, J.P., and 
White, D.E.: Use of tumor- infiltrating lymphocytes and interleukin-2 in 
the immunotherapy of patients with metastatic melanoma. A preliminary 
report. N. Engl. J. Med. 319:1676-1680, 1988. 
23. Melder, R.J., Whiteside, T.L. , Vujanovic, N.L. , Hiserodt, J.C., 
Herberman, R.B.: A new approach to generating antitumor effectors for 
adoptive immunotherapy using human adherent l 3 rmphokine- activated 
killer cells. Cancer Res 48: 3461-3469, 1988. 
Recombinant DNA Research, Volume 14 
[853] 
